|
1
|
Modinger Y, Loffler B, Huber-Lang M and
Ignatius A: Complement involvement in bone homeostasis and bone
disorders. Semin Immunol. 37:53–65. 2018. View Article : Google Scholar : PubMed/NCBI
|
|
2
|
Khosla S: Pathogenesis of age-related bone
loss in humans. J Gerontol A Biol Sci Med Sci. 68:1226–1235. 2013.
View Article : Google Scholar :
|
|
3
|
Bonewald LF: The amazing osteocyte. J Bone
Miner Res. 26:229–238. 2011. View
Article : Google Scholar : PubMed/NCBI
|
|
4
|
Winkler DG, Sutherland MK, Geoghegan JC,
Yu C, Hayes T, Skonier JE, Shpektor D, Jonas M, Kovacevich BR,
Staehling-Hampton K, et al: Osteocyte control of bone formation via
sclerostin, a novel BMP antagonist. EMBO J. 22:6267–6276. 2003.
View Article : Google Scholar : PubMed/NCBI
|
|
5
|
Delgado-Calle J, Sato AY and Bellido T:
Role and mechanism of action of sclerostin in bone. Bone. 96:29–37.
2017. View Article : Google Scholar :
|
|
6
|
Rauch F and Adachi R: Sclerostin: More
than a bone formation brake. Sci Transl Med. 8:330fs72016.
View Article : Google Scholar : PubMed/NCBI
|
|
7
|
Roforth MM, Fujita K, McGregor UI, Kirmani
S, McCready LK, Peterson JM, Drake MT, Monroe DG and Khosla S:
Effects of age on bone mRNA levels of sclerostin and other genes
relevant to bone metabolism in humans. Bone. 59:1–6. 2014.
View Article : Google Scholar
|
|
8
|
Ardawi MS, Rouzi AA, Al-Sibiani SA,
Al-Senani NS, Qari MH and Mousa SA: High serum sclerostin predicts
the occurrence of osteoporotic fractures in postmenopausal women:
The Center of Excellence for Osteoporosis Research Study. J Bone
Miner Res. 27:2592–2602. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
9
|
Li X, Warmington KS, Niu QT, Asuncion FJ,
Barrero M, Grisanti M, Dwyer D, Stouch B, Thway TM, Stolina M, et
al: Inhibition of sclerostin by monoclonal antibody increases bone
formation, bone mass, and bone strength in aged male rats. J Bone
Miner Res. 25:2647–2656. 2010. View
Article : Google Scholar : PubMed/NCBI
|
|
10
|
Finkel T: Signal transduction by reactive
oxygen species. J Cell Biol. 194:7–15. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
11
|
Schieber M and Chandel NS: ROS function in
redox signaling and oxidative stress. Curr Biol. 24:R453–R462.
2014. View Article : Google Scholar : PubMed/NCBI
|
|
12
|
Witko-Sarsat V, Friedlander M,
Capeillere-Blandin C, Nguyen-Khoa T, Nguyen AT, Zingraff J, Jungers
P and Descamps-Latscha B: Advanced oxidation protein products as a
novel marker of oxidative stress in uremia. Kidney Int.
49:1304–1313. 1996. View Article : Google Scholar : PubMed/NCBI
|
|
13
|
Capeillere-Blandin C, Gausson V,
Descamps-Latscha B and Witko-Sarsat V: Biochemical and
spectrophotometric significance of advanced oxidized protein
products. Biochim Biophys Acta. 1689:91–102. 2004. View Article : Google Scholar : PubMed/NCBI
|
|
14
|
Witko-Sarsat V, Friedlander M, Nguyen Khoa
T, Capeillere-Blandin C, Nguyen AT, Canteloup S, Dayer JM, Jungers
P, Drüeke T and Descamps-Latscha B: Advanced oxidation protein
products as novel mediators of inflammation and monocyte activation
in chronic renal failure. J Immunol. 161:2524–2532. 1998.PubMed/NCBI
|
|
15
|
Wu Q, Zhong ZM, Zhu SY, Liao CR, Pan Y,
Zeng JH, Zheng S, Ding RT, Lin QS, Ye Q, et al: Advanced oxidation
protein products induce chondrocyte apoptosis via receptor for
advanced glycation end products-mediated, redox-dependent intrinsic
apoptosis pathway. Apoptosis. 21:36–50. 2016. View Article : Google Scholar
|
|
16
|
Xie F, Sun S, Xu A, Zheng S, Xue M, Wu P,
Zeng JH and Bai L: Advanced oxidation protein products induce
intestine epithelial cell death through a redox-dependent, c-jun
N-terminal kinase and poly (ADP-ribose) polymerase-1-mediated
pathway. Cell Death Dis. 5:e10062014. View Article : Google Scholar : PubMed/NCBI
|
|
17
|
Wu Q, Zhong ZM, Pan Y, Zeng JH, Zheng S,
Zhu SY and Chen JT: Advanced oxidation protein products as a novel
marker of oxidative stress in postmenopausal osteoporosis. Med Sci
Monit. 21:2428–2432. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
18
|
Kalousova M, Skrha J and Zima T: Advanced
glycation end-products and advanced oxidation protein products in
patients with diabetes mellitus. Physiol Res. 51:597–604. 2002.
|
|
19
|
Liu Z, Yao X, Jiang W, Li W, Zhu S, Liao
C, Zou L, Ding R and Chen J: Advanced oxidation protein products
induce microglia-mediated neuroinflammation via MAPKs-NF-κB
signaling pathway and pyroptosis after secondary spinal cord
injury. J Neuroinflammation. 17:902020. View Article : Google Scholar
|
|
20
|
Witko-Sarsat V, Gausson V, Nguyen AT,
Touam M, Drueke T, Santangelo F and Descamps-Latscha B:
AOPP-induced activation of human neutrophil and monocyte oxidative
metabolism: A potential target for N-acetylcysteine treatment in
dialysis patients. Kidney Int. 64:82–91. 2003. View Article : Google Scholar : PubMed/NCBI
|
|
21
|
Sun S, Xie F, Xu X, Cai Q, Zhang Q, Cui Z,
Zheng Y and Zhou J: Advanced oxidation protein products induce
S-phase arrest of hepatocytes via the ROS-dependent,
β-catenin-CDK2-mediated pathway. Redox Biol. 14:338–353. 2018.
View Article : Google Scholar
|
|
22
|
Zhu SY, Zhuang JS, Wu Q, Liu ZY, Liao CR,
Luo SG, Chen JT and Zhong ZM: Advanced oxidation protein products
induce pre-osteoblast apoptosis through a nicotinamide adenine
dinucleotide phosphate oxidase-dependent, mitogen-activated protein
kinases-mediated intrinsic apoptosis pathway. Aging Cell.
17:e127642018. View Article : Google Scholar : PubMed/NCBI
|
|
23
|
Zhang YB, Zhong ZM, Hou G, Jiang H and
Chen JT: Involvement of oxidative stress in age-related bone loss.
J Surg Res. 169:e37–42. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
24
|
Zeng JH, Zhong ZM, Li XD, Wu Q, Zheng S,
Zhou J, Ye WB, Xie F, Wu XH, Huang ZP and Chen JT: Advanced
oxidation protein products accelerate bone deterioration in aged
rats. Exp Gerontol. 50:64–71. 2014. View Article : Google Scholar
|
|
25
|
Bouxsein ML, Boyd SK, Christiansen BA,
Guldberg RE, Jepsen KJ and Muller R: Guidelines for assessment of
bone microstructure in rodents using micro-computed tomography. J
Bone Miner Res. 25:1468–1486. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
26
|
Livak KJ and Schmittgen TD: Analysis of
relative gene expression data using real-time quantitative PCR and
the 2(-Delta Delta C(T)) method. Method. 25:402–408. 2001.
View Article : Google Scholar
|
|
27
|
Coulson J, Bagley L, Barnouin Y, Bradburn
S, Butler-Browne G, Gapeyeva H, Hogrel JY, Maden-Wilkinson T, Maier
AB, Meskers C, et al: Circulating levels of dickkopf-1,
osteoprotegerin and sclerostin are higher in old compared with
young men and women and positively associated with whole-body bone
mineral density in older adults. Osteoporos Int. 28:2683–2689.
2017. View Article : Google Scholar : PubMed/NCBI
|
|
28
|
Manolagas SC: From estrogen-centric to
aging and oxidative stress: A revised perspective of the
pathogenesis of osteoporosis. Endocr Rev. 31:266–300. 2010.
View Article : Google Scholar : PubMed/NCBI
|
|
29
|
Shi XY, Hou FF, Niu HX, Wang GB, Xie D,
Guo ZJ, Zhou ZM, Yang F, Tian JW and Zhang X: Advanced oxidation
protein products promote inflammation in diabetic kidney through
activation of renal nicotinamide adenine dinucleotide phosphate
oxidase. Endocrinology. 149:1829–1839. 2008. View Article : Google Scholar : PubMed/NCBI
|
|
30
|
Cohen-Kfir E, Artsi H, Levin A, Abramowitz
E, Bajayo A, Gurt I, Zhong L, D'Urso A, Toiber D, Mostoslavsky R
and Dresner-Pollak R: Sirt1 is a regulator of bone mass and a
repressor of Sost encoding for sclerostin, a bone formation
inhibitor. Endocrinology. 152:4514–4524. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
31
|
Hwang JW, Yao H, Caito S, Sundar IK and
Rahman I: Redox regulation of SIRT1 in inflammation and cellular
senescence. Free Radic Biol Med. 61:95–110. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
32
|
Zhong ZM, Bai L and Chen JT: Advanced
oxidation protein products inhibit proliferation and
differentiation of rat osteoblast-like cells via NF-kappaB pathway.
Cell Physiol Biochem. 24:105–114. 2009. View Article : Google Scholar : PubMed/NCBI
|
|
33
|
Ding R, Jiang H, Sun B, Wu X, Li W, Zhu S,
Liao C, Zhong Z and Chen J: Advanced oxidation protein products
sensitized the transient receptor potential vanilloid 1 via NADPH
oxidase 1 and 4 to cause mechanical hyperalgesia. Redox Biol.
10:1–11. 2016. View Article : Google Scholar : PubMed/NCBI
|
|
34
|
Artsi H, Cohen-Kfir E, Gurt I, Shahar R,
Bajayo A, Kalish N, Bellido TM, Gabet Y and Dresner-Pollak R: The
Sirtuin1 activator SRT3025 down-regulates sclerostin and rescues
ovariectomy-induced bone loss and biomechanical deterioration in
female mice. Endocrinology. 155:3508–3515. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
35
|
Stegen S, Stockmans I, Moermans K,
Thienpont B, Maxwell PH, Carmeliet P and Carmeliet G: Osteocytic
oxygen sensing controls bone mass through epigenetic regulation of
sclerostin. Nat Commun. 9:25572018. View Article : Google Scholar : PubMed/NCBI
|
|
36
|
Liu SX, Hou FF, Guo ZJ, Nagai R, Zhang WR,
Liu ZQ, Zhou ZM, Zhou M, Xie D, Wang GB and Zhang X: Advanced
oxidation protein products accelerate atherosclerosis through
promoting oxidative stress and inflammation. Arterioscler Thromb
Vasc Biol. 26:1156–1162. 2006. View Article : Google Scholar : PubMed/NCBI
|
|
37
|
Li HY, Hou FF, Zhang X, Chen PY, Liu SX,
Feng JX, Liu ZQ, Shan YX, Wang GB, Zhou ZM, et al: Advanced
oxidation protein products accelerate renal fibrosis in a remnant
kidney model. J Am Soc Nephrol. 18:528–538. 2007. View Article : Google Scholar : PubMed/NCBI
|
|
38
|
Komosinska-Vassev K, Olczyk P,
Winsz-Szczotka K, Kuznik-Trocha K, Klimek K and Olczyk K: Age- and
gender-related alteration in plasma advanced oxidation protein
products (AOPP) and glycosaminoglycan (GAG) concentrations in
physiological ageing. Clin Chem Lab Med. 50:557–563. 2012.
View Article : Google Scholar : PubMed/NCBI
|
|
39
|
Bonewald LF: Osteocytes as dynamic
multifunctional cells. Ann N Y Acad Sci. 1116:281–290. 2007.
View Article : Google Scholar : PubMed/NCBI
|
|
40
|
Dallas SL, Prideaux M and Bonewald LF: The
osteocyte: An endocrine cell and more. Endocr Rev. 34:658–690.
2013. View Article : Google Scholar : PubMed/NCBI
|
|
41
|
van Bezooijen RL, ten Dijke P, Papapoulos
SE and Lowik CW: SOST/sclerostin, an osteocyte-derived negative
regulator of bone formation. Cytokine Growth Factor Rev.
16:319–327. 2005. View Article : Google Scholar : PubMed/NCBI
|
|
42
|
Li XF, Zhang Y, Kang H, Liu W, Liu P,
Zhang J, Harris SE and Wu D: Sclerostin binds to LRP5/6 and
antagonizes canonical Wnt signaling. J Biol Chem. 280:19883–19887.
2005. View Article : Google Scholar : PubMed/NCBI
|
|
43
|
Balemans W, Patel N, Ebeling M, Van Hul E,
Wuyts W, Lacza C, Dioszegi M, Dikkers FG, Hildering P, Willems PJ,
et al: Identification of a 52 kb deletion downstream of the SOST
gene in patients with van Buchem disease. J Med Genet. 39:91–97.
2002. View Article : Google Scholar : PubMed/NCBI
|
|
44
|
Balemans W, Ebeling M, Patel N, Van Hul E,
Olson P, Dioszegi M, Lacza C, Wuyts W, Van Den Ende J, Willems P,
et al: Increased bone density in sclerosteosis is due to the
deficiency of a novel secreted protein (SOST). Hum Mol Genet.
10:537–543. 2001. View Article : Google Scholar : PubMed/NCBI
|
|
45
|
Zhang D, Park BM, Kang M, Nam H, Kim EJ,
Bae C and Lim SK: The systemic effects of sclerostin overexpression
using φC31 integrase in mice. Biochem Biophys Res Commun.
472:471–476. 2016. View Article : Google Scholar : PubMed/NCBI
|
|
46
|
Cosman F, Crittenden DB, Adachi JD,
Binkley N, Czerwinski E, Ferrari S, Hofbauer LC, Lau E, Lewiecki
EM, Miyauchi A, et al: Romosozumab treatment in postmenopausal
women with osteoporosis. N Engl J Med. 375:1532–1543. 2016.
View Article : Google Scholar : PubMed/NCBI
|
|
47
|
Yu C, Huang D, Wang K, Lin B, Liu Y, Liu
S, Wu W and Zhang H: Advanced oxidation protein products induce
apoptosis, and upregulate sclerostin and RANKL expression, in
osteocytic MLO-Y4 cells via JNK/p38 MAPK activation. Mol Med Rep.
15:543–550. 2017. View Article : Google Scholar :
|
|
48
|
Finkel T and Holbrook NJ: Oxidants,
oxidative stress and the biology of ageing. Nature. 408:239–247.
2000. View Article : Google Scholar : PubMed/NCBI
|
|
49
|
Baur JA, Ungvari Z, Minor RK, Le Couteur
DG and de Cabo R: Are sirtuins viable targets for improving
healthspan and lifespan? Nat Rev Drug Discov. 11:443–461. 2012.
View Article : Google Scholar : PubMed/NCBI
|
|
50
|
Zainabadi K: Drugs targeting SIRT1, a new
generation of therapeutics for osteoporosis and other bone related
disorders? Pharmacol Res. 143:97–105. 2019. View Article : Google Scholar : PubMed/NCBI
|
|
51
|
Kim HN, Han L, Iyer S, de Cabo R, Zhao H,
O'Brien CA, Manolagas SC and Almeida M: Sirtuin1 suppresses
osteoclastogenesis by deacetylating FoxOs. Mol Endocrinol.
29:1498–1509. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
52
|
El-Haj M, Gurt I, Cohen-Kfir E, Dixit V,
Artsi H, Kandel L, Yakubovsky O, Safran O and Dresner-Pollak R:
Reduced Sirtuin1 expression at the femoral neck in women who
sustained an osteoporotic hip fracture. Osteoporos Int.
27:2373–2378. 2016. View Article : Google Scholar : PubMed/NCBI
|
|
53
|
Caito S, Rajendrasozhan S, Cook S, Chung
S, Yao H, Friedman AE, Brookes PS and Rahman I: SIRT1 is a
redox-sensitive deacetylase that is post-translationally modified
by oxidants and carbonyl stress. Faseb J. 24:3145–3159. 2010.
View Article : Google Scholar : PubMed/NCBI
|
|
54
|
Furukawa A, Tada-Oikawa S, Kawanishi S and
Oikawa S: H2O2 accelerates cellular
senescence by accumulation of acetylated p53 via decrease in the
function of SIRT1 by NAD+ depletion. Cell Physiol
Biochem. 20:45–54. 2007. View Article : Google Scholar
|
|
55
|
Farr JN and Khosla S: Skeletal changes
through the lifespan-from growth to senescence. Nat Rev Endocrinol.
11:513–521. 2015. View Article : Google Scholar : PubMed/NCBI
|
